AU Patent

AU3247899A — New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide

Assigned to Novo Nordisk AS · Expires 1999-09-20 · 27y expired

What this patent protects

This invention relates to salt forms of (2E)-5- amino-5methylhex-2- enoic acid N-methyl-N-((1R)-1- (N-methyl-N-((1R)-1- (methylcarbamoyl)-2-phenylethyl)carbamoyl)-2- (2-naphthyl)ethyl)amide, preparation thereof and use as therapeutic agent.

USPTO Abstract

This invention relates to salt forms of (2E)-5- amino-5methylhex-2- enoic acid N-methyl-N-((1R)-1- (N-methyl-N-((1R)-1- (methylcarbamoyl)-2-phenylethyl)carbamoyl)-2- (2-naphthyl)ethyl)amide, preparation thereof and use as therapeutic agent.

Drugs covered by this patent

Patent Metadata

Patent number
AU3247899A
Jurisdiction
AU
Classification
—
Expires
1999-09-20
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.